Shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) have been assigned an average rating of “Moderate Buy” from the fifteen brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $92.9333.
HSIC has been the subject of a number of research reports. Weiss Ratings raised shares of Henry Schein from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, August 21st. Piper Sandler upped their price objective on shares of Henry Schein from $91.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. BTIG Research raised their target price on Henry Schein from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, August 19th. Barclays reaffirmed an “overweight” rating and set a $100.00 price target (up from $86.00) on shares of Henry Schein in a research report on Thursday, August 6th. Finally, Stifel Nicolaus set a $95.00 price target on Henry Schein in a report on Wednesday, August 5th.
View Our Latest Analysis on HSIC
Henry Schein Stock Down 1.2%
Henry Schein (NASDAQ:HSIC – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.03. The firm had revenue of $3.46 billion during the quarter, compared to analyst estimates of $3.37 billion. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.Henry Schein’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.10 EPS. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. On average, research analysts forecast that Henry Schein will post 5.36 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the business. CYBER HORNET ETFs LLC purchased a new position in shares of Henry Schein in the 2nd quarter valued at $25,000. MUFG Securities EMEA plc acquired a new stake in shares of Henry Schein in the 2nd quarter worth $27,000. Operose Advisors LLC purchased a new stake in shares of Henry Schein in the second quarter valued at about $33,000. Federated Hermes Inc. purchased a new stake in shares of Henry Schein in the fourth quarter valued at about $32,000. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Henry Schein during the fourth quarter worth about $37,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.
In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.
Recommended Stories
- Five stocks we like better than Henry Schein
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
